Carbiotix AXOS included in Chalmers CVD study
Carbiotix AB (publ) ("Carbiotix") announces today that the company’s AXOS food ingredient (corn fiber extract containing AXOS) will be used in a 6-week cardiometabolic intervention study managed by Chalmers University and financed in part by FORMAS (Swedish Research Council for Sustainable Development), to be carried out in Italy during H2 2020. This study will provide valuable clinical data demonstrating the efficacy of AXOS as a food ingredient targeting people suffering from Cardiovascular Disease (CVD). The study is also in line with Carbiotix overall strategy to provide its AXOS ingredient for independent third-party financed studies.
The study called “DiGuMet”, or Diet x Gut microbiome-based Metabotypes, was established to tailor intervention strategies to improve health. The study will be managed by Chalmers University and includes the Universitá degli Studi di Napoli Federico II and Universitat de Barcelona, in collaboration with the Danish Cancer Society and Italian food company Barilla. The project is 100% funded by the national research councils of each university, FORMAS in the case of Chalmers University. Planned for H2 2020, the 6-week intervention study will focus on fermentable vs. non-fermentable cereal fiber across 80 subjects with two distinct microbiota related metabotypes, targeting primarily postprandial glucose response (after meal) to determine cardio-metabolic risk and tailor intervention strategies to improve health. CVDs are the number one cause of death globally, taking an estimated 18 million lives each year. (1)
Kristofer Cook, CEO for Carbiotix, comments
“I am very pleased with the decision to include AXOS in this cardiometabolic intervention study and look forward to reviewing the results. With this study, AXOS related ingredients will now be used in four planned intervention studies targeting four different leading disease areas. These include type-2 diabetes (through Lund University), hyperammonemia, and IBD (managed by Carbiotix) and now CVD (managed by Chalmers University). As we scale-up the production of AXOS, we are now in a position to provide food ingredient and medical food samples in large enough quantities to be included in our own and third-party financed studies. We have seen an increased interest among industrial and academic actors to include AXOS in their studies and we will continue to support this trend as a means to promote the prebiotic advantages of AXOS, and assist with its inclusion in food & beverage and nutraceutical products as an ingredient, as well as a co-treatment for therapeutics.”
This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the company’s contact person set out below on 4 June 2020.
Forward-looking statements This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
For further information:
Kristofer Cook, CEO
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.